Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis
Recruiting · NCT06998628 · Interventional (participants receive a specific treatment) · Lead sponsor: Tanta University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA can affect any joint, it typically involves the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as the wrists and knees. Symptoms related to the joints and surrounding tissues include swelling, tenderness upon touch, morning stiffness, and significant difficulty moving the affected joints
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) \[9\] i.e., 28 joints disease activity score (DAS 28) \>2.6.
- Patients receiving the conventional DMARDs.
- Both sexes.
- Age range between 18and 70 years old
Exclusion criteria
- Patients with retinal or cerebral hemorrhage.
- Patients with renal and hepatic dysfunction.
- Patients with hypersensitivity to study medications.
- Pregnant and lactating females.
- Patients receiving biological or synthetic DMARDs
Where it is running
1 location listed.
- Faculty of Medicine, Al-Azhar University - Damietta, Damietta Governorate, Egypt